- $2.78bn
- $3.64bn
- $1.36bn
- 88
- 67
- 73
- 90
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.26 | ||
| PEG Ratio (f) | 1.31 | ||
| EPS Growth (f) | 9.39% | ||
| Dividend Yield (f) | 1.69% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.05 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 22.9 | ||
| Price to Sales | 2.11 | ||
| EV to EBITDA | 10.01 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.87% | ||
| Return on Equity | 19.6% | ||
| Operating Margin | 19.05% | ||
Financial Summary
| Year End 29th Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 870.46 | 993.2 | 1,168.66 | 1,309.06 | 1,360.82 | 1,323.89 | 1,397.2 | 6.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -35.79 | -0.44 | +67.36 | +22.5 | +18.91 | +24.19 | +7.49 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.
Directors
- Ellen Zane NEC (70)
- Christopher Simon PRE (57)
- William Burke CFO (53)
- Anila Lingamneni EVP (54)
- Michelle Basil EVP (49)
- Josep Llorens SVP (59)
- Lloyd Johnson DRC (67)
- Robert Abernathy IND (66)
- Catherine Burzik IND (71)
- Michael Coyle IND (59)
- Charles Dockendorff IND (67)
- Mark Kroll IND (68)
- Claire Pomeroy IND (66)
- Last Annual
- March 29th, 2025
- Last Interim
- December 27th, 2025
- Incorporated
- August 29th, 1985
- Public Since
- October 17th, 1979
- No. of Shareholders
- 96
- No. of Employees
- 3,023
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 46,829,249
- Address
- 125 Summer Street, BOSTON, 02110
- Web
- https://www.haemonetics.com
- Phone
- +1 7818487100
- Contact
- Olga Guyette
- Auditors
- Ernst & Young LLP
Upcoming Events for HAE
Q4 2026 Haemonetics Corp Earnings Release
Haemonetics Corp Annual Shareholders Meeting
Similar to HAE
Abbott Laboratories
New York Stock Exchange
Accendra Health
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
What is the Haemonetics share price?
As of Today at 11:00 UTC, shares in Haemonetics are trading at $59.34. This share price information is delayed by 15 minutes.
How has the Haemonetics share price performed this year?
Shares in Haemonetics last closed at $59.34 and the price had moved by -5.79% over the past 365 days. In terms of relative price strength the Haemonetics share price has underperformed the S&P500 Index by -18.11% over the past year.
What are the analyst and broker recommendations for Haemonetics?
The overall consensus recommendation for Haemonetics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Haemonetics dividend yield?
Haemonetics does not currently pay a dividend.
Does Haemonetics pay a dividend?
Haemonetics does not currently pay a dividend.
When does Haemonetics next pay dividends?
Haemonetics does not currently pay a dividend.
How do I buy Haemonetics shares?
To buy shares in Haemonetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Haemonetics?
As of the previous close price of $59.34, shares in Haemonetics had a market capitalisation of $2.78bn.
Where are Haemonetics shares listed?
Here are the trading details for Haemonetics:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: HAE
What kind of share is Haemonetics?
Based on an overall assessment of its quality, value and momentum Haemonetics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Haemonetics share price forecast for 2026?
The analyst consensus target price for shares in Haemonetics is $87.90. That is 48.13% above the last closing price of $59.34.
Analysts covering Haemonetics currently have a consensus Earnings Per Share (EPS) forecast of $4.95 for the next financial year.
Find out moreWhat is the trend in the Haemonetics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Haemonetics. Over the past six months, its share price has outperformed the S&P500 Index by +1.05%.
As of the last closing price of $59.34, shares in Haemonetics were trading -10.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Haemonetics PE Ratio?
The Haemonetics PE ratio based on its reported earnings over the past 12 months is 11.26. The shares last closed at $59.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Haemonetics?
Haemonetics' management team is headed by:
- Ellen Zane - NEC
- Christopher Simon - PRE
- William Burke - CFO
- Anila Lingamneni - EVP
- Michelle Basil - EVP
- Josep Llorens - SVP
- Lloyd Johnson - DRC
- Robert Abernathy - IND
- Catherine Burzik - IND
- Michael Coyle - IND
- Charles Dockendorff - IND
- Mark Kroll - IND
- Claire Pomeroy - IND